Neonatal livers are a potential source of good-quality hepatocytes for clinical transplantation. We compared viability and function of neonatal hepatocytes (NHs) and adult hepatocytes (AHs) and report their clinical use both intraportally and in alginate microbeads. Following isolation from donor livers, hepatocyte function was assessed using albumin, alpha-1-antitrypsin, and factor VII. Metabolic function was investigated by measuring resorufin conjugation, ammonia metabolism, uridine diphosphate glucuronosyltransferase enzyme activity, and cytochrome P450 (CYP) function following induction. Activation of the instant blood-mediated inflammatory reaction by NHs and AHs was investigated using an in vitro blood perfusion model, and tissue factor expression was analyzed using real-time polymerase chain reaction (RT-PCR). Clinical hepatocyte transplantation (HT) was undertaken using standard protocols. Hepatocytes were isolated from 14 neonatal livers, with an average viability of 89.4% 6 1.8% (mean 6 standard error of the mean) and average yield of 9.3 3 10 6 6 2.0 3 10 6 cells/g. Hepatocytes were isolated from 14 adult livers with an average viability of 78.6% 6 2.4% and yield 2.2 3 10 6 6 0.5 3 10 5 cells/g. NHs had significantly higher viability after cryopreservation than AHs, with better attachment efficiency and less plasma membrane leakage. There were no differences in albumin, alpha-1-antitrypsin, and factor VII synthesis between NHs and AHs (P > 0.05). Neonatal cells had inducible phase 1 enzymes as assessed by CYP function and functional phase 2 enzymes, in which activity was comparable to AHs. In an in vitro blood perfusion model, AHs elicited increased thrombus formation with a greater consumption of platelets and white cells compared with NHs (28.3 3 10 9 versus 118.7 3 10 9 and 3.3 3 10 9 versus 6.6 3 10 9 ; P < 0.01). Intraportal transplantation and intraperitoneal transplantation of alginate encapsulated hepatocytes was safe, and preliminary data suggest the cells may activate the immune response to a lesser degree than adult cells. In conclusion, we have shown NHs have excellent cell viability, function, and drug metabolism making them a suitable alternative source for clinical HT.
Hepatocyte transplantation (HT) has demonstrated some promise as an alternative to liver transplantation (LT) for children with liver-based metabolic diseases and acute liver failure (ALF). Because of the shortage of donor organs, pediatric patients often face a long wait for an appropriately sized organ of sufficient quality to become available. As a result, HT is being explored as an alternative. Significant improvement in metabolic function has been demonstrated following HT in children with liver-based metabolic disease. However, efficacy beyond 18 months has yet to be shown.
Human hepatocytes are isolated from whole donor livers or segments unsuitable for whole organ transplantation, using a collagenase perfusion technique and purified using centrifugation.
(1-3) For patients with liver-based metabolic diseases, the cells are administered under radiological guidance into the portal vein (PV), from which they migrate across the sinusoidal endothelial barrier and engraft in the parenchyma. Successful engraftment depends on the ability of hepatocytes to survive the innate immune system and successfully transverse the sinusoids. Viability and function of transplanted hepatocytes is associated with the quality of liver tissue from which they are isolated. In the case of children with ALF, administration of hepatocytes intraportally is challenging, particularly in the coagulopathic, critically ill patient. As an alternative, injection of alginate-encapsulated hepatocyte microbeads into the intraperitoneal cavity is a newly described approach, in which the semipermeable gel alginate allows the entry of oxygen and nutrients into the microbead, whereas simultaneously protecting the hepatocytes against the immune system. (4) One of the major limitations of the technique is that the cells are largely derived from poor-quality livers that have otherwise been rejected for transplantation, thus the quality of the cells themselves is often very poor.
Neonatal livers have recently been explored as a cell source for HT to overcome this major limitation. Neonatal livers are rarely used for solid organ transplantation due to the high incidence of hepatic artery thrombosis, which may result from decreased or absent protein C synthesis by the donor liver. (5) Instead, they may be offered for hepatocyte isolation for the purpose of cell transplantation. Transplantation of human neonatal hepatocytes (NHs) into a rat model of CriglerNajjar syndrome showed animals that received NHs had significantly higher concentrations of uridine diphosphate glucuronosyltransferase (UGT) 1 family, polypeptide A1, and conjugated bilirubin expression at both 3 days and 6 months compared with adult cells. Functionality of NHs has also been shown in 4 patients with severe urea cycle disorders, showing metabolic stabilization for 4-13 months following transplantation. (6, 7) In the United Kingdom, the introduction of new guidelines defining brain death in newborns has increased the number of donor organs that are offered for hepatocyte isolation, resulting in an increased requirement to characterize these cells in the context of HT. (8) The aim of this study was to investigate whether NHs are a suitable alternative to adult hepatocytes (AHs). To investigate this, we compared viability, functionality, drug metabolism, and procoagulant effects of these cells. We also describe 3 patients for whom HT was undertaken using neonatal cells.
Patients and Methods
Ethical approval for the isolation of primary human hepatocytes was obtained from the National Research Ethics Service (King's College Hospital local research ethics committee; LREC 01-016). The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki.
Organs are donated through the National Health Service Blood and Transplant (NHSBT) and offered for HT following decline for solid organ transplantation with appropriate consent in place for clinical and research use.
NEONATAL LIVER PROCUREMENT
For donation after circulatory death (DCD), maximum warm ischemia time (WIT) was usually set at 90 minutes. In the absence of an alternative definition for neonatal WIT, the adult definition is used, which is the time from oxygen saturation of 70% or systolic pressure of 50 mm Hg (depending on which agonal observation occurs first) to aortic cannulation. DCD and donation after brain death (DBD) were accepted according to guidelines published by the Royal College of Paediatrics and Child Health. (8) The cold ischemia time (CIT) is defined as the time from aortic cannulation to hepatocyte isolation. For pediatric DCD procurement, asystole was awaited after withdrawal of life support. Following declaration of death and a 5-minute stand-off period, a thoraco-abdominal incision was made, followed by abdominal aorta cannulation and cross-clamp in the chest. Depending on vessel Abbreviations: AAT, alpha-1 anti-trypsin; AH, adult hepatocyte; ALF, acute liver failure; CIT, cold ischemia time; CYP, cytochrome P450; DAPI, 4 0 ,6-diamidino-2-phenylindole; DBD, donation after brain death; DCD, donation after circulatory death; DMSO, dimethyl sulfoxide; EDTA, ethylene diamine tetraacetic acid; ELISA, enzymelinked immunosorbent assay; HEPES, 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid; HT, hepatocyte transplantation; IBMIR, instant blood-mediated inflammatory reaction; IL, interleukin; INR, international normalized ratio; LCU, luminescent counting units; LDH, lactate dehydrogenase; LT, liver transplantation; MCP-1, monocyte chemoattractant protein 1; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NH, neonatal hepatocyte; NHSBT, National Health Service Blood and Transplant; NIHR, National Institute for Health Research; n.s., not significant; OD, optical density; OMP, omeprazole; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; PHE, phenobarbital; PVC, polyvinyl chloride; PV, portal vein; RIF, rifampicin; RT, room temperature; RT-PCR, real-time polymerase chain reaction; SEM, standard error of the mean; SRB, sulforhodamine B; TF, tissue factor; TNF-a, tumor necrosis factor a; UDPGA, uridine 5 0 diphosphoglucuronic acid; UGT, uridine diphosphate glucuronosyltransferase; UW, University of Wisconsin; VEGF, vascular endothelial growth factor; WCC, white cell count; WE, Williams E; WIT, warm ischemia time.
size, the PV was cannulated either in the hilum or via the small mesenteric vein in the root of the small bowel mesentery. In situ 500 mL of ice-cold University of Wisconsin (UW) solution was perfused through the aorta and PV followed by rapid hepatectomy. A further 250-500 mL of UW solution was perfused through the PV and hepatic artery until the effluent became clear. Cold static storage was the standard.
NH ISOLATION
Primary hepatocytes were isolated from whole livers as described by Mitry et al. (9, 10) Briefly, major blood vessels on the liver surface were cut, cannulated, and secured through suturing. The tissue was perfused at a flow rate of 50 mL/minute with buffer (calcium-free Hank's balanced salt solution, 1 M 4-[2-hydroxyethyl]-1-piperazine ethanesulfonic acid [HEPES] and 0.5 mM EGTA), followed by calcium-free Hank's balanced salt solution and Eagle's minimum essential medium containing 0.05% collagenase (VitaCyte, Indianapolis, IN). Once digested, the tissue was minced and sieved. Hepatocytes were purified by washing 3 times in ice-cold Eagle's minimum essential medium and centrifuged at 50g at 48C for 5 minutes. Cells used were cryopreserved in UW solution with 5% glucose and 10% dimethyl sulfoxide (DMSO) using a controlled rate freezer (Kryo 10, series III, Planer Products, Ltd., Middlesex, UK) and stored at 21408C.
THAWING AND CULTURE OF CRYOPRESERVED PRIMARY HEPATOCYTES
All assays were carried out using hepatocytes that had been cryopreserved and thawed. Cryopreserved hepatocytes were thawed at 378C, resuspended in Williams E (WE) medium and centrifuged at 50g for 5 minutes at 48C. Cells were resuspended and viability determined using the trypan blue exclusion assay. Hepatocytes were cultured in WE containing the following: 50 lg/mL heat-inactivated fetal bovine serum; 10 mM HEPES; penicillin, 100 U/mL; streptomycin, 100 lg/ mL; insulin, 10 mg/L; transferrin, 5.5 mg/L; selenium, 6.7 lg/L; 10 -7 M dexamethasone; and 2 mM Lglutamine. There were 96-well plates that were coated with 0.1 mg/mL rat-tail collagen type 1 overnight and washed with phosphate-buffered saline (PBS).
ASSESSMENT OF HEPATOCYTE VIABILITY, ATTACHMENT, AND PLASMA MEMBRANE DAMAGE 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide Assay
Hepatocyte viability was determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Briefly, cells were cultured for 24 hours at 378C, 5% CO 2 , the supernatant removed and cells further cultured with serum free medium containing 0.5 mg/mL of MTT (Sigma Aldrich, Dorset, UK) for 4 hours. The produced formazan was dissolved in DMSO and the optical density read at 570 nm on a Dynex MRX microplate reader (see Supporting Materials for more details).
Sulforhodamine B Assay
A sulforhodamine B (SRB) assay was carried out to determine cell attachment. Hepatocytes were cultured for 24 hours at 378C, 5% CO 2 . Supernatant was removed and replaced with 50% trichloroacetic acid, cells were washed, and SRB was added before solubilization in 1% acetic acid. The optical density was read at 564 nm on a Dynex MRX microplate reader (see Supporting Materials for more details). 
Lactate Dehydrogenase Assay
Plasma membrane damage following cryopreservation was measured using a lactate dehydrogenase (LDH) assay (Pierce LDH cytotoxicity kit, Thermo Fisher Scientific, Paisley, UK). Cells were cultured for 24 hours at 378C, 5% CO 2 . Sterile water was added to control cells, which represented spontaneous LDH activity. Lysis buffer was added to other wells, which represented maximum LDH activity. Reaction mixture was added and absorbance read at 490 nm and 680 nm (background signal). LDH activity was quantified as the percentage of spontaneous LDH activity over the maximum LDH activity (see Supporting Materials for more details).
ASSESSMENT OF HEPATOCYTE METABOLIC FUNCTION
Albumin, Alpha-1-Antitrypsin, and Factor VII Synthesis
For functional assays, media were collected 12 hours after plating and enzyme immunoasssays carried out for human albumin (Bethyl Laboratories Inc.), alpha-1-antitrypsin (Bethyl Laboratories), and factor VII (Assaypro, St. Charles, MO) according to the manufacturer's instructions (see Supporting Materials for more details). Values were normalized to protein content using a bicinchoninic acid assay protein assay (see Supporting Materials).
Ammonia Metabolism
Urea synthesis was measured using a QuantiChrom Urea Assay kit (Universal Biologicals, Cambridge, UK). Cells were washed with PBS and treated with 5 mM ammonium chloride (Sigma Aldrich, Dorset, UK) for 6 hours before measurement of urea synthesis (see Supporting Materials for more details).
Phase 2 Assay
Phase 2 activity was measured by quantifying the conjugation of resorufin. Cells were cultured for 24 hours at 378C, 5% CO 2 . Following incubation, 10 lg/mL of resorufin was added for 2 hours at 378C, 5% CO 2 . Resorufin values were measured at 0 hours and 2 hours and the concentration of resorufin calculated using a standard curve (1.56-100 ng/mL). Values at 2 hours were subtracted from the 0 hour time point to measure the decrease of fluorescent resorufin due to its conjugation.
UGT Activity
UGT activity was measured using a UGT-Glo assay (Promega, Southampton, UK). Cells were cultured at 378C, 5% CO 2 for 24 hours. To measure UGT activity, cells were treated with or without 50 lM of uridine 5 0 diphosphoglucuronic acid (UDPGA) and proluciferin substrates (50 lM UGT multienzyme mix) for 1 hour at 378C, 5% CO 2 . Following incubation, 50 lL of detection agent was added to samples and the luminescence was recorded immediately on FLUOstar Omega Microplate Reader (BMG Labtech, Ortenbery, Germany) from 0 to 20 minutes every 1 minute, integration time 1 second. Values shown are the cells without UDPGA minus the cells with UDPGA as a percentage of the cells without UDPGA.
7-Ethoxyresorufin-O-Deethylase Assay
Cytochrome P450 (CYP) 1A1/1A2 activity was assessed by measuring the conversion of 7-ethoxyresorufin to resorufin. Cells were cultured for 24 hours at 378C, 5% CO 2 . Cells were treated with 20 lM 7-ethoxyresorufin and 1.5 mM salicylamide and the concentration of resorufin calculated using a standard curve (1.56-100 ng/ml).
CYP Assays
CYP1A1, 1A2, 2C9, 3A4, and 3A7 activity were measured using a commercial P450-Glo cell-based assay (Promega, Southampton, UK) according to the manufacturer's instructions. Hepatocytes were cultured for 24 hours at 378C, 5% CO 2 , and CYP activity was induced every day for 3 days before detection of cytochrome activity. CYP1A1/1A2 activity was induced using 50 lM of omeprazole (OMP); CYP2C9 and CYP2B6 activity was induced using 1 mM of phenobarbital (PHE); and CYP3A4 and CYP3A7 activity was induced using 25 lM of rifampicin (RIF). Following 3 days of induction, 50 lL of luciferin substrate was added/well (luciferin-CEE/CYP1A1, 1:50; luciferin-ME/CYP1A2, 1:50; luciferin-H/CYP2C9, 1:50; luciferin-IPA/CYP3A4, 1:1000; luciferin-CEE/CYP3 A7, 1:50). Cells were incubated with the luciferin substrate for 60 minutes (CYP3A4) and 3 hours (CYP1A1, 1A2, 3A4, and 3A7). Following incubation, 50 lL of detection agent was added to samples and the luminescence recorded immediately on FLUOstar Omega Microplate Reader (BMG Labtech, Ortenberg, Germany) from 0 to 20 minutes every 1 minute, integration time 1 second. Values were normalized to DNA content using Quant-IT Picogreen (Thermo Fisher Scientific; see Supporting Materials for more details).
CHANDLER LOOP MODEL
A Chandler loop model was designed based on previous reports. (11, 12) Briefly, custom-made clinical grade polyvinyl chloride (PVC) tubing (3 3 16 inch) coated in heparin using end point attached heparin technology (Medtronic Carmeda Bioactive Surface, Watford, UK) was filled with 6 mL of ABO-matched blood containing the relevant samples and closed into circuits with heparin-coated polystyrene connectors. Tubing loops were rotated at 24 rpm and incubated at 378C for 0, 15, 30, and 60 minutes. Samples were taken with a Pasteur pipette into 1 mL ethylene diamine tetraacetic acid (EDTA) tubes (1.8 mg EDTA per mL of blood).
Whole blood samples were immediately analyzed for full blood counts on an ADIVA 2120 hematology system (Siemens Healthcare Diagnostics, Surrey, UK). The remaining samples were centrifuged at 2000g for 15 minutes to obtain the plasma. Samples were stored at 2808C until analysis.
Cytokine expression was analyzed using a highsensitivity Randox HS X Biochip Array designed to measure 12 cytokines/chemokines (interleukin [IL 
Protein Expression
For analysis of tissue factor expression, hepatocytes were plated in 4-well chamber slides at 250,000 cells/chamber and incubated at 378C, 5% CO 2 overnight. Slides were prepared for staining as described previously. Sections were stained with a primary rabbit monoclonal tissue factor antibody (Abcam, Cambridge, UK) at a 1:50 dilution for 1 hour at room temperature (RT)
CLINICAL HT
A national HT program is in operation at King's College Hospital, London. Children are referred for either intraportal infusion of hepatocytes for liver-based metabolic disease or for intraperitoneal infusion of alginate encapsulated hepatocytes for ALF. Hepatocytes may be used either fresh or cryopreserved. Hepatocytes must meet minimum viability and microbiological criteria prior to clinical cell transplantation.
For liver-based metabolic disease, radiologically guided intraportal infusion of hepatocytes is undertaken via the umbilical vein if patent and the ductus venosus is closed or accessed surgically via the inferior mesenteric vein at laparotomy. Cells are infused while measuring portal pressure. Standard immunosuppression is with corticosteroids, basiliximab, and tacrolimus. Prophylactic broad-spectrum antibiotics are used for 48 hours.
Children with ALF who meet criteria for LT may be candidates for HT in the form of alginate microbead infusion. Microbeads are formed of hepatocytes encapsulated in ultrapure sterile-alginate (NovaMatrix, Norway) using an Encapsulator B-390 pro (Buchi, Oldham, UK) forming microbeads of approximately 500 lM in size. These microbeads are infused into the intraperitoneal cavity via a wide-bore cannula under ultrasound guidance. No immunosuppression is required because alginate is bio-inert and shields the hepatocyte from the immune system. Broad spectrum antibiotics are administered for 48 hours at least. After full recovery (usually 1 month), the microbeads are removed using a laparoscopic peritoneal lavage, or they are removed at time of LT.
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STATISTICAL ANALYSIS
Normality was tested by using the Kolgrov-Smirnov normality test. For normally distributed data (MTT, viability at isolation, postthawing viability, and yield), data were evaluated using a 2-tailed unpaired t test. For nonparametric data (SRB, albumin, and urea), data were analyzed using the Mann-Whitney U test. In Chandler loop samples and clinical data, sample size was not sufficient for appropriate statistical tests. All data are expressed as mean 6 standard error of the mean (SEM). All data were analyzed using GraphPad Prism, version 5 (GraphPad Software, La Jolla, CA).
Results

VIABILITY AND YIELD
Hepatocytes were isolated from 14 neonatal livers (Table 1 ; Fig. 1 ; DBD, n 5 3; DCD, n 5 11), with an average viability of 89.4% 6 1.8% and average yield of 9.3 3 10 6 6 2.0 3 10 6 cells/g. For comparison, hepatocytes were isolated from 14 adult livers (aged >16 years), with an average viability of 78.6% 6 2.4% and average yield 2.2 3 10 6 6 0.5 3 10 5 cells/g (Fig.  1A,B) . AHs used as controls were taken from the latest 14 isolations in order to accurately represent the quality of cells that result from livers currently offered to the program and to avoid era bias. Following cryopreservation and thawing, mean viability of NHs was significantly higher compared with AHs ( Fig. 1C ; 77.6% 6 3.6% versus 59.2% 6 2.5%; n 5 9; P < 0.001). MTT assay after cell plating demonstrated NHs had significantly higher viability than AHs ( Fig. 1D ; OD; 1.0 6 0.2 versus 0.4 6 0.1; P < 0.05). A LDH assay was used to measure plasma membrane damage of cryopreserved hepatocytes. AHs had significantly higher LDH leakage following cryopreservation and thawing compared with NHs ( Fig. 1E ; 70.7% 6 10.5% versus 43.4% 6 5.2%; P < 0.05).
CELL MORPHOLOGY AND ATTACHMENT EFFICIENCY
An SRB attachment assay showed cryopreserved NHs had significantly higher attachment efficiency than AHs ( Fig. 1F,G ; OD, 2.4 6 0.3 versus 0.6 6 0.03; P < 0.01). Images demonstrate NHs formed complete monolayers on collagen-coated plates 24 hours after plating, whereas AHs are rounded with low confluence.
HEPATOCYTE FUNCTION
There was no significant difference in the production of liver-specific proteins; albumin, alpha-1-antitrypsin, and factor VII synthesis between NHs and AHs at 1 day after plating ( Fig. 2A-C left) and AHs (right) 24 hours after plating on collagen coated plates *P < 0.05; **P < 0.001; ***P < 0.001. Data represent mean 6 SEM.
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and proluciferin UGT multi-enzyme substrates showed neonatal function of UGT enzymes was comparable to AHs ( Fig. 2F ; 30.0% 6 7.2% versus 37.7% 6 4.0% UGT substrate consumed; n 5 3; P > 0.05).
DRUG METABOLISM OF NHs
To determine the ability of NHs to metabolize drug compounds, different CYP isoforms were investigated following a 3-day induction. A total of 3 out of 5 neonatal batches tested showed increased CYP activity following induction with OMP (CYP1A2) and PHE (CYP2C9 and CYP2B6; Fig. 3 ; see Supporting Table  1 ). A total of 4 out of 5 batches of NHs showed increased activity of CYP3A4 and CYP3A7 following induction with RIF ( Fig. 3 ; see Supporting Table 1 ). These results are comparable to AHs, which are not all inducible following the isolation and cryopreservation process (data not shown). Phase 1 activity was further investigated by measuring the conversion of 7-ethoxyresorufin to resorufin. CYP1A1/1A2 of NHs was comparable to that of AHs following induction with OMP for 3 days ( Fig. 2; 1 .9 6 0.1 versus 3.3 6 0.3 of resorufin formed/minute/ million cells).
NHs AND THE EFFECT ON THROMBUS FORMATION IN VITRO
An in vitro tubing loop model (Chandler loop) was used to compare how NHs and AHs trigger activation of the coagulation cascade when in contact with ABOmatched blood. (13, 14) AHs elicited a visible thrombus formation and a drop-in platelet count after 60 minutes compared with NHs and control blood-only samples ( Fig. 4A ; platelet count 28. 3 3 10 9 [AH] versus 118.7 3 10 9 [NH] versus 214.3 3 10 9 cell/L; n 5 3). Furthermore, after 60 minutes, AHs caused a decrease in circulating white cells compared with NHs ( Fig. 4B; 3.3 310 9 versus 6.6 310 9 versus 5.8 310 9 ; n 5 3). There was no difference between NHs and AHs in the expression of the complement protein C5b-9. These preliminary results suggest NHs may not trigger coagulation activation and platelet/white cell consumption to the same extent as AHs. To investigate the potential mechanisms of instant blood-mediated inflammatory reaction (IBMIR) activation by hepatocytes, tissue factor expression was quantified. Immunofluorescent staining showed AHs had strong expression of tissue factor in the cytosol. Tissue factor expression was absent in hepatocytes derived from NHs (Fig. 4D) . This was further confirmed by qPCR analysis for the tissue factor gene. This showed that AHs had significantly higher tissue factor expression than NHs ( Fig. 4E ; relative expression 2.1 6 0.2 versus 0.3 6 0.1; n 5 5; P < 0.001). Cytokine analysis showed there were no differences in IL2, IL6, IL8, VEGF, TNF-a, IL1a, MCP1, EGF, and IL1RA, although NHs did show a trend toward higher IL10 production (see Supporting Materials).
CLINICAL USE OF NHs
Three children have undergone transplantation of NHs in our center to date. Two of these children underwent the procedure for ALF and received cryopreserved NHs encapsulated in alginate microbeads injected into the intraperitoneal cavity while awaiting LT. One child with a rare inborn error of sulfite metabolism received cryopreserved NHs via the intraportal route.
Child 1 and 2 with ALF were aged 24 and 18 months, respectively, at the time of HT. Child 1 was born prematurely and diagnosed with ALF due to neonatal hemochromatosis liver disease (siderosis on salivary gland biopsy) with persistent and worsening liver function despite treatment with exchange transfusion and intravenous immunoglobulin. She was listed for LT but due to her small size an organ was not readily available.
FIG. 3.
Induction of CYP enzymes in human NHs and AHs. Hepatocytes were cultured for 24 hours at 378C, 5% CO 2 and cytochrome metabolism induced every day for 3 days before detection of cytochrome activity (A) CYP1A2 activity in NHs measured by luciferin-ME following treatment with 50 lM OMP or DMSO control (B) CYP2C9 activity in NHs measured by Luciferin-H following treatment with 1 mM PHE or DMSO control (C) CYP2B6 activity in NHs measured by Luciferin-2B6 following treatment with 1 mM PHE or DMSO control (D) CYP3A4 activity in NHs measured by Luciferin-IPA following treatment with 25 lM RIF or DMSO control (E) CYP3A7 activity in NHs measured by Luciferin-PFBE following treatment with 25 lM RIF or DMSO control. (F) CYP1A1/1A2 activity in NHs and AHs was assessed by measuring the conversion of 7-ethoxyresorufin to resorufin following induction with 50 lM OMP or DMSO controls for 3 days.
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The patient underwent hepatocyte microbead transplantation 12 days after admission: 40 mL of infusate containing 3 310 7 /kg neonatal cells (first infusion) and 2.3 3 10 7 /kg neonatal cells (second infusion) which were tolerated well without any adverse effects. This patient survived for a further 31 days with supportive management at which time a suitable organ became available and she underwent LT. Microbeads were washed out at time of the LT. Adhesions were not noted at laparotomy. She is well now 2.5 years after transplant.
Child 2 presented with coagulopathy (international normalized ratio [INR], 7) and encephalopathy at the age of 18 months. He was listed for LT but as no organ became immediately available he underwent microbead transplantation as a bridging intervention day 2 of admission. The patient received a total of 1.7 3 10 7 /kg NHs and made a full recovery with a normal INR 10 days after microbead transplantation, and he did not suffer any adverse events. Microbeads were washed out 6 months after infusion at which time some fibrous bands between clumps of cells and the omentum were described at laparoscopy. Nine months later, he presented with an INR of 17 and encephalopathy at which time he was listed once again for LT and received an organ shortly after listing. At time of LT, clumps of microbeads were retrieved but adhesions were not observed and the child remains well 6 months after LT.
Child 3 was diagnosed with a rare inborn error of sulfite metabolism, which is associated with irreversible neurological damage and early death. The patient underwent intraportal infusion of a total 6.6 3 10 8 cryopreserved hepatocytes over 4 infusions, with the first transplantation on day 2 of life. Biochemical stability was achieved, with sulfite and urinary s-sulfocysteine lower than expected, given previous experience with infants suffering this condition, though it is not possible to draw firm conclusions regarding the efficacy of HT from the improvement in biochemical parameters alone.
Discussion
We suggest that neonatal livers, currently not used for organ transplant, may be an ideal cell source for HT. NHs have high viability, attachment efficiency, and metabolic function after cryopreservation and may be a suitable alternative to AHs. Results from the Chandler loop model suggest that NHs may not activate coagulation to the same extent as AHs and may express less TF. In a small sample of patients, NHs were shown to be suitable for clinical HT, with no patients showing adverse effects.
The ability to cryopreserve hepatocytes is essential, so they can be stored until needed for emergency treatment. This is one of the major advantages of HT versus LT. However, the cryopreservation process adversely affects viability, function, and attachment efficiency of hepatocytes, with LDH leakage significantly increased upon thawing. (15) Hepatocytes derived from NHs are able to withstand the cryopreservation and thawing process significantly better than AHs, with significantly greater viability and less LDH leakage. Further research is required into the molecular membrane structure of NHs and AHs and how this may affect cryopreservation. The use of NHs that have high viability after thawing has the potential to increase the stock of good-quality hepatocytes used for off-the-shelf emergency HT.
Fully functional NHs are vital to the success of HT to provide sufficient enzyme function to rescue the enzyme-deficient recipient. However, theoretical concerns have arisen about the functional maturity of neonatal cells. Newborn liver function is still in development during the early postnatal period, and there is a decreased ability of the neonatal liver to metabolize and detoxify xenobiotic substances. (16) We have shown that albumin, alpha-1-antitrypsin, factor VII synthesis, and ammonia metabolism in NHs is comparable to AHs, suggesting NHs are functionally suitable for transplantation. Studies into the development of hepatic drug-metabolizing enzymes have found that each enzyme system has its own pattern of development. (17) CYP3A7 is the primary isoform expressed in the neonatal period and declines rapidly after birth, with CYP3A4 taking over its function within the first few weeks of life. We found that in hepatocytes from 4 out of 5 neonatal donors tested there was inducible CYP3A7 and CYP3A4 activity. The expression of CYP1A2 is the last enzyme to develop, only present by 1 to 2 months of life. (17) This is reflected by our results, with very low levels of CYP1A2 induction in 3 out of 5 cells from neonatal donors. Higher levels of induction in some neonatal cells may be related to drugs received prior or shortly after birth, including PHE and midazolam. Quantitative data into the development of the phase 2 enzymes are limited, but it has been suggested that the UGT enzymes, which metabolize 15% of all drugs, are triggered at birth and reach adult levels by 3 months. (17) This suggests NHs should have functioning phase 2 enzymes, which is reflected in our results that show resorufin conjugation and UGT substrate consumption was similar to adult cells.
In animal models, up to a 6-fold loss of hepatocytes has been observed within the first 24 hours of cell transplantation, with studies relating this early cell loss to activation of coagulation and complement cascades described as the IBMIR. (13, 14, 18, 19) The IBMIR may be triggered by the expression of tissue factor on the donor hepatocytes. (20) Neonatal cells may potentially be less thrombotic and immunogenic than adult liver-derived cells, allowing increased engraftment and function. Initial results using the Chandler loop model suggest NHs do not cause platelet consumption and circulating white cell loss to the same extent as AH. There is some variability in the platelet counts of blood samples containing NHs compared with AHs, which may be related to the age of the donor. Further experiments are required to determine if lower immunogenicity is observed within the first few days of life. Significant differences have been described between neonatal and adult coagulation systems with concentrations of vitamin K-dependent factors II, VII, IX, and X and contact factors XI and XII reduced to approximately 50% of normal adult values. (21) (22) (23) Furthermore, activated partial thromboplastin time is prolonged in healthy full-term infants compared with adults. (24) We found tissue factor expression was decreased in NHs compared with adult cells, which may partly explain the decreased coagulation activation. Potentially, if neonatal cells do not activate coagulation to the same extent as AHs, cells have a much better chance of cell survival, providing sustained function for children with metabolic liver disease, without the need for multiple infusions.
Previous work published on NHs considered WITs and CITs a major limiting factor in isolating goodquality hepatocytes, with ideal CIT being limited to 2.5 hours and WIT not exceeding 30 minutes, based on previous in vitro studies. (6, 25, 26) However, we have shown CITs of up to 8 hours and WITs of up to 84 minutes can still produce hepatocytes with a high viability and yield. It is possible neonatal organs are able to withstand longer periods of ischemia due to their high quality yet the mechanisms involved in this process remain to be found. Although we have characterized NH and AH viability and function in vitro, we have yet to prove their clinical efficacy. A larger patient cohort is required to validate the enzymatic function of these cells in a range of liver-based metabolic diseases.
In conclusion, the use of neonatal livers as a cell source for HT may significantly increase the number of high-quality cells available for transplantation, with the advantage of excellent cell viability, function, and potentially lower activation of the IBMIR of cells. NHs have been used in a clinical context, and though proof of clinical efficacy is still elusive, noninvasive markers of immune activation were decreased with use of neonatal cells. This cell source may significantly improve the clinical outcomes of HT for pediatric ALF or inborn errors of metabolism.
